Extended Data Figure 2 : SOX2 is expressed in benign and malignant chemical-induced skin tumours and in genetically induced skin tumours from different cells of origin.

From: SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma

Extended Data Figure 2

a, Quantification of the proportion of SOX2+ skin tumours assessed by immunostaining for SOX2 protein (n ≥ 6 sections analysed from 43 papillomas and 13 SCCs). b, c, Co-immunostaining of K14 (white), CD34 (green) and SOX2 protein (red) in papilloma (b) and SCC (c), showing expression of SOX2 within CD34+ K14+ TECs. d, FACS quantification of SOX2–GFP+ cells in CD34+ and CD34 TECs (LinEpcam+) within benign papillomas and malignant SCCs (n = 12 papillomas and 26 carcinomas from at least 10 mice). e, Proportion of SOX2+ papillomas arising from Kras(G12D) expression either in interfollicular epidermis and infundibulum (InvCreER:KrasG12D) or in hair follicle stem cells and their progeny (K19CreER:KrasG12D), as assessed by SOX2 immunostaining. f, Representative co-immunostaining of SOX2 protein (red) and K14 (green) in papilloma from InvCreER:KrasG12D and K19CreER:KrasG12D mice. These data show that SOX2 expression is found in papillomas arising from different epidermal origins. g, Proportion of SCCs containing SOX2+ TECs among SCCs arising from Kras(G12D) expression and p53 deletion either in interfollicular epidermis and infundibulum cells preferentially (K14CreER:KrasG12D:p53cKO), or in hair follicle stem cells and their progeny (Lgr5CreER:KrasG12D:p53cKO). h, Representative co-immunostaining of SOX2 protein (red) and K14 (green) in SCCs from K14CreER:KrasG12D:p53cKO and Lgr5CreER:KrasG12D:p53cKO mice. These data show that SOX2 expression is found in SCCs from different cellular origins. Epi, tumour epithelia cells; Str, stroma. Hoechst nuclear staining is represented in blue. Scale bars, 50 μm. Data represent the mean and s.e.m.